



Material from Lancet SA Newsletter - Compiled by Dr. Ben Prinsloo - January 2011

Introduction

Invasive disease from *Streptococcus pneumoniae* (pneumococcus) is a major cause of illness and death.

Guidelines have been updated for use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults, according to a 2010 issue of MMWR. (Morbidity and Mortality Weekly Report.)



Specific updated Advisory Committee on Immunization Practices (ACIP) recommendations for administration of PPSV23 among adults 19 years or older include the following:

- Adults aged 19 to 64 years with chronic or immunosuppressive medical conditions, including asthma, should receive PPSV23.
- For adults aged 19 to 64 years who smoke cigarettes, PPSV23 administration and smoking cessation guidance are recommended.
- At age 65 years, all persons should receive PPSV23 vaccination. Persons given PPSV23 for any indication before age 65 years should be given another dose of PPSV23 at 65 years or older if 5 years or more have passed since their previous dose. Persons who receive PPSV23 at or after age 65 years should receive only a single dose.
- For persons aged 19 to

64 years with functional or anatomic asplenia and for persons with immunocompromising conditions, a second dose of PPSV23 should be given 5 years after the first dose. However, because of uncertainty regarding clinical benefit and safety, the ACIP does not recommend multiple revaccinations.


Other Indications for Administration

Underlying medical conditions or other indications for administration of PPSV23 among adults aged 19 to 64 years include the following:

- Immunocompetent persons with chronic heart disease (excluding hypertension); chronic lung disease including chronic obstructive pulmonary disease, emphysema, and asthma; diabetes mellitus; Cerebrospinal fluid leaks; cochlear implant; alcoholism; chronic liver

disease, including cirrhosis; and cigarette smoking;

- Persons with functional or anatomic asplenia (sickle cell disease and other hemoglobinopathies; congenital or acquired asplenia, splenic dysfunction, or splenectomy);
- Immunocompromised persons with congenital or acquired immunodeficiencies (including B- [humoral] or T-lymphocyte deficiency, complement deficiencies [particularly C1, C2, C3, and C4 deficiencies], and phagocytic disorders other than chronic granulomatous disease); HIV infection; chronic renal failure; nephrotic syndrome; leukemias; lymphomas; Hodgkin's disease; generalized malignancy; diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids or radiation therapy; solid organ transplantation; and multiple myeloma.



Preparations include:

- Imovax Pneumo 23 (Sanofi Pasteur)
- Pneumovax 23 (MSD)

Dose: IM, 0.5mL

Adapted from Medscape EDUCATION
Infectious Diseases 2010

Main Laboratory / Headquarters
5th Avenue Office Suites
Opp. Traffic HQ - Upper Hill
5th Ngong Avenue | Ngong Road
| Switchboard: 0703 061 000
Landlines: 020 273 5123, 271
6701 | 020 2508456, 271 6697
Mobile: 0729 111110, 0736
493100
Email: info@lancet.co.ke
Website: www.lancet.co.ke

PATHOLOGISTS LANCET KENYA BRANCHES

LANCET- MOMBASA
Biashara Building,
Tel: 0721 143 766

LANCET- KISUMU
WEDCO Centre on Oginga Odinga Street
Tel: 0726 838773

LANCET- THIKA
Thika Arcade
Tel: 020262 2633/ 0717414684

LANCET- EASTLEIGH
Alliance Medical Centre Madina Shopping
Mall Avenue Tel: 0717 414682

LANCET GA
Within Zenith Medical Centre
Tel: 0726 995 860

Prof. NELSON AWORI CENTRE
Next to Nairobi Hospital Tel: 0726 839341

LANCET- BURUBURU
Buruburu service point behind Misora
Tel: 0717414708

LANCET GARISSA
Mabruk House
Mobile: 0704 819 799

LANCET- ELDORET
KVDA Plaza
Tel: 0714 403 655

LANCET- PARKLANDS
Park Place , 1st floor
Tel: 0708727628

LANCET MALINDI
At Tawfiq Hospital
Mobile: 0721 143 766/

Mombasa – Links Plaza
Links Road, Nyali
Mobile: 0722 355 796